|
A Phase 1b study of Psilocybin Assisted Psychotherapy to address fear of recurrence in patients diagnosed with early-stage breast cancer and ovarian cancer in remission
Outpatient CTRC, University of Colorado Hospital A study conducted to determine if a single dose of 25 mg. of psilocybin, in combination with therapy, will address fear of recurrence in patients diagnosed with early-stage breast cancer and ovarian cancer in remission... |
|
Cardiometabolic consequences of the loss of ovarian function (LILAC Study)
Outpatient CTRC, University of Colorado Hospital We are inviting premenopausal women (women with regular menstrual periods) to participate in a study looking at the effects of estrogen and menopause on body composition and vascular function. ... |
|
Protocol NRG-BR009, A Phase III Adjuvant Trial Evaluating the Addition of Adjuvant Chemotherapy to Ovarian Function Suppression plus Endocrine Therapy in Premenopausal Patients with pN0-1, ER-Positive/HER2-Negative Breast Cancer and an Oncotype Recurrence Score less than or equal to 25 (OFSET)
Cherry Creek Medical Center, Highlands Ranch Hospital, Lone Tree Medical Center, Memorial Hospital Central, Memorial Hospital North, University of Colorado Hospital Younger age at diagnosis is an adverse prognostic factor in early breast cancer: women who are less than 35 years of age at diagnosis are more likely to die from their disease than their older counterparts following standard treatments. There remains a pressing need for advancements in the... |
|
Genetic Engagement, Education, and Screening (CU-GENES) Study
Department Specific Free Standing Clinic, University of Colorado Hospital This study plans to implement a community-based genetic testing program for hereditary cancer risk in a higher risk population. The study team will partner with the Colorado Ovarian Cancer Alliance (COCA) and the Jewish Community Center (JCC) to provide educational events to the Jewish com... |
|
A211801, "BRCA-P: A Randomized, Double-Blind, Placebo-Controlled, Multi-Center, International Phase 3 Study to Determine the Preventive Effect of Denosumab on Breast Cancer in Women Carrying a BRCA1 Germline Mutation,"
University of Colorado Hospital PRIMARY OBJECTIVE: I. To evaluate the reduction in the risk of any breast cancer (invasive or ductal carcinoma in situ [DCIS]) in women with germline BRCA1 mutation who are treated with denosumab compared to placebo. SECONDARY OBJECTIVES: I. To determine the reduction in the risk ... |